Cardiac amyloidosis is a disease characterized by the deposition of misfolded proteins in the myocardium, leading to restrictive cardiomyopathy. It comprises two subtypes: immunoglobulin light chain cardiac amyloidosis (AL) and transthyretin cardiac amyloidosis (ATTR). ATTR is classified as wild-type (wtATTR) and hereditary (hATTR), depending on the presence or absence of a transthyretin (TTR) genetic mutation. The diagnosis of cardiac amyloidosis is challenging due to nonspecific symptoms with other cardiac conditions, often resulting in misdiagnosis. This mini review provides an in-depth analysis of cardiac amyloidosis, focusing on its subtypes, clinical manifestations, diagnostic multimodal imaging, and recent therapeutic advancements.
References
[1]
Sanchorawala, V. (2024) Systemic Light Chain Amyloidosis. New England Journal of Medicine, 390, 2295-2307. https://doi.org/10.1056/nejmra2304088
[2]
Raval, M., Siddiq, S., Sharma, K., Sanghvi, L., Jain, A., Patel, S., et al. (2023) A Review of Recent Advances in the Diagnosis of Cardiac Amyloidosis, Treatment of Its Cardiac Complications, and Disease-Modifying Therapies. F1000Research, 12, Article 192. https://doi.org/10.12688/f1000research.130285.1
[3]
Porcari, A., Fontana, M. and Gillmore, J.D. (2022) Transthyretin Cardiac Amyloidosis. Cardiovascular Research, 118, 3517-3535. https://doi.org/10.1093/cvr/cvac119
[4]
Ruberg, F.L., Grogan, M., Hanna, M., Kelly, J.W. and Maurer, M.S. (2019) Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 73, 2872-2891. https://doi.org/10.1016/j.jacc.2019.04.003
[5]
Dorbala, S., Cuddy, S. and Falk, R.H. (2020) How to Image Cardiac Amyloidosis: A Practical Approach. JACC: Cardiovascular Imaging, 13, 1368-1383. https://doi.org/10.1016/j.jcmg.2019.07.015
[6]
Ioannou, A., Patel, R.K., Razvi, Y., Porcari, A., Sinagra, G., Venneri, L., et al. (2022) Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis over the Course of 20 Years. Circulation, 146, 1657-1670. https://doi.org/10.1161/circulationaha.122.060852
[7]
Allegra, A., Mirabile, G., Tonacci, A., Genovese, S., Pioggia, G. and Gangemi, S. (2023) Machine Learning Approaches in Diagnosis, Prognosis and Treatment Selection of Cardiac Amyloidosis. International Journal of Molecular Sciences, 24, Article 5680. https://doi.org/10.3390/ijms24065680
[8]
Bukhari, S. (2023) Cardiac Amyloidosis: State-of-the-Art Review. Journal of Geriatric Cardiology, 20, 361-375. https://doi.org/10.26599/1671-5411.2023.05.006
[9]
Rubin, J. and Maurer, M.S. (2020) Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. Annual Review of Medicine, 71, 203-219. https://doi.org/10.1146/annurev-med-052918-020140
[10]
Kittleson, M.M., Maurer, M.S., Ambardekar, A.V., Bullock-Palmer, R.P., Chang, P.P., Eisen, H.J., et al. (2020) Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement from the American Heart Association. Circulation, 142, e7-e22. https://doi.org/10.1161/cir.0000000000000792
[11]
Heidenreich, P.A., Bozkurt, B., Aguilar, D., Allen, L.A., Byun, J.J., Colvin, M.M., et al. (2022) AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 79, e263-e421.
[12]
Tziomalos, G., Zegkos, T., Baltagianni, E., Bazmpani, M., Exadaktylou, P., Parcharidou, D., et al. (2025) Transthyretin Amyloid Cardiomyopathy: Current Diagnostic Approach and Risk Stratification with Multimodality Imaging. Journal of Clinical Medicine, 14, Article 2014. https://doi.org/10.3390/jcm14062014
[13]
Kravchenko, D., Isaak, A., Zimmer, S., Öztürk, C., Mesropyan, N., Bischoff, L.M., et al. (2024) Parametric Mapping Using Cardiovascular Magnetic Resonance for the Differentiation of Light Chain Amyloidosis and Transthyretin-Related Amyloidosis. European Heart Journal-Cardiovascular Imaging, 25, 1451-1461. https://doi.org/10.1093/ehjci/jeae154
[14]
Martinez-Naharro, A., Treibel, T.A., Abdel-Gadir, A., Bulluck, H., Zumbo, G., Knight, D.S., et al. (2017) Magnetic Resonance in Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology, 70, 466-477. https://doi.org/10.1016/j.jacc.2017.05.053
[15]
Fontana, M., Ćorović, A., Scully, P. and Moon, J.C. (2019) Myocardial Amyloidosis. JACC: Cardiovascular Imaging, 12, 2345-2356. https://doi.org/10.1016/j.jcmg.2019.06.023
[16]
Ioannou, A., Patel, R.K., Razvi, Y., Porcari, A., Knight, D., Martinez-Naharro, A., et al. (2023) Multi-Imaging Characterization of Cardiac Phenotype in Different Types of Amyloidosis. JACC: Cardiovascular Imaging, 16, 464-477. https://doi.org/10.1016/j.jcmg.2022.07.008
[17]
Ahammed, M.R. and Ananya, F.N. (2024) Cardiac Amyloidosis: A Comprehensive Review of Pathophysiology, Diagnostic Approach, Applications of Artificial Intelligence, and Management Strategies. Cureus, 16, e63673. https://doi.org/10.7759/cureus.63673
[18]
Gertz, M.A. (2023) Immunoglobulin Light Chain Amyloidosis: 2024 Update on Diagnosis, Prognosis, and Treatment. American Journal of Hematology, 99, 309-324. https://doi.org/10.1002/ajh.27177
[19]
Muchtar, E., Dispenzieri, A., Magen, H., Grogan, M., Mauermann, M., McPhail, E.D., et al. (2020) Systemic Amyloidosis from a (AA) to T (ATTR): A Review. Journal of Internal Medicine, 289, 268-292. https://doi.org/10.1111/joim.13169
[20]
Adams, D., Ando, Y., Beirão, J.M., Coelho, T., Gertz, M.A., Gillmore, J.D., et al. (2021) Expert Consensus Recommendations to Improve Diagnosis of ATTR Amyloidosis with Polyneuropathy. Journal of Neurology, 268, 2109-2122. https://doi.org/10.1007/s00415-019-09688-0
[21]
Yamamoto, H. and Yokochi, T. (2019) Transthyretin Cardiac Amyloidosis: An Update on Diagnosis and Treatment. ESC Heart Failure, 6, 1128-1139. https://doi.org/10.1002/ehf2.12518
[22]
Jung, M., Chang, S., Han, E.J. and Youn, J. (2022) Multimodal Imaging and Biomarkers in Cardiac Amyloidosis. Diagnostics, 12, Article 627. https://doi.org/10.3390/diagnostics12030627
[23]
Chacko, L., Martone, R., Cappelli, F. and Fontana, M. (2019) Cardiac Amyloidosis: Updates in Imaging. Current Cardiology Reports, 21, Article No. 108. https://doi.org/10.1007/s11886-019-1180-2
[24]
Liang, S., Liu, Z., Li, Q., He, W. and Huang, H. (2023) Advance of Echocardiography in Cardiac Amyloidosis. Heart Failure Reviews, 28, 1345-1356. https://doi.org/10.1007/s10741-023-10332-3
[25]
Korosoglou, G., Giusca, S., André, F., aus dem Siepen, F., Nunninger, P., Kristen, A.V., et al. (2021) Diagnostic Work-Up of Cardiac Amyloidosis Using Cardiovascular Imaging: Current Standards and Practical Algorithms. Vascular Health and Risk Management, 17, 661-673. https://doi.org/10.2147/vhrm.s295376
[26]
Starr, N., Ioannou, A. and Martinez-Naharro, A. (2024) Monitoring Cardiac Amyloidosis with Multimodality Imaging. Revista Española de Cardiología (English Edition), 77, 79-87. https://doi.org/10.1016/j.rec.2023.06.014
Scheel, P.J., Mukherjee, M., Hays, A.G. and Vaishnav, J. (2022) Multimodality Imaging in the Evaluation and Prognostication of Cardiac Amyloidosis. Frontiers in Cardiovascular Medicine, 9, Article 787618. https://doi.org/10.3389/fcvm.2022.787618
[29]
Hanna, M., Ruberg, F.L., Maurer, M.S., Dispenzieri, A., Dorbala, S., Falk, R.H., et al. (2020) Cardiac Scintigraphy with Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week. Journal of the American College of Cardiology, 75, 2851-2862. https://doi.org/10.1016/j.jacc.2020.04.022
[30]
Wang, T.K.M., Hassan, O.K.A., Jaber, W. and Xu, B. (2020) Multi-Modality Imaging of Cardiac Amyloidosis: Contemporary Update. World Journal of Radiology, 12, 87-100. https://doi.org/10.4329/wjr.v12.i6.87
[31]
Briasoulis, A., Bampatsias, D., Papamichail, A., Kuno, T., Skoularigis, J., Xanthopoulos, A., et al. (2023) Invasive and Non-Invasive Diagnostic Pathways in the Diagnosis of Cardiac Amyloidosis. Journal of Cardiovascular Development and Disease, 10, Article 256. https://doi.org/10.3390/jcdd10060256
[32]
Castiglione, V., Franzini, M., Aimo, A., Carecci, A., Lombardi, C.M., Passino, C., et al. (2021) Use of Biomarkers to Diagnose and Manage Cardiac Amyloidosis. European Journal of Heart Failure, 23, 217-230. https://doi.org/10.1002/ejhf.2113
[33]
Ogieuhi, I.J., Ugiomoh, O.M., Muzofa, K., Callender, K., Ayodeji, J.D., Nnekachi, N.P., et al. (2024) Tafamidis Therapy in Transthyretin Amyloid Cardiomyopathy: A Narrative Review from Clinical Trials and Real-World Evidence. The Egyptian Heart Journal, 76, Article No. 90. https://doi.org/10.1186/s43044-024-00517-y
[34]
Dohrn, M.F., Ihne, S., Hegenbart, U., Medina, J., Züchner, S.L., Coelho, T., et al. (2020) Targeting Transthyretin‐Mechanism‐Based Treatment Approaches and Future Perspectives in Hereditary Amyloidosis. Journal of Neurochemistry, 156, 802-818. https://doi.org/10.1111/jnc.15233
[35]
Ioannou, A., Fontana, M. and Gillmore, J.D. (2023) RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis. BioDrugs, 37, 127-142. https://doi.org/10.1007/s40259-023-00577-7
[36]
Griffin, J.M., Rosenthal, J.L., Grodin, J.L., Maurer, M.S., Grogan, M. and Cheng, R.K. (2021) ATTR Amyloidosis: Current and Emerging Management Strategies: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology, 3, 488-505. https://doi.org/10.1016/j.jaccao.2021.06.006
[37]
Maurer, M.S. (2022) Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy. The American Journal of Cardiology, 185, S23-S34. https://doi.org/10.1016/j.amjcard.2022.10.014
[38]
Bampatsias, D., Wardhere, A. and Maurer, M.S. (2024) Treatment of Transthyretin Cardiac Amyloidosis. Current Opinion in Cardiology, 39, 407-416. https://doi.org/10.1097/hco.0000000000001156
[39]
Dohy, Z., Szabo, L., Pozsonyi, Z., Csecs, I., Toth, A., Suhai, F.I., et al. (2022) Potential Clinical Relevance of Cardiac Magnetic Resonance to Diagnose Cardiac Light Chain Amyloidosis. PLOS ONE, 17, e0269807. https://doi.org/10.1371/journal.pone.0269807
[40]
Wu, Z. and Yu, C. (2021) Diagnostic Performance of CMR, SPECT, and PET Imaging for the Detection of Cardiac Amyloidosis: A Meta-Analysis. BMC Cardiovascular Disorders, 21, Article No. 482. https://doi.org/10.1186/s12872-021-02292-z
[41]
Clerc, O.F., Vijayakumar, S. and Dorbala, S. (2024) Radionuclide Imaging of Cardiac Amyloidosis: An Update and Future Aspects. Seminars in Nuclear Medicine, 54, 717-732. https://doi.org/10.1053/j.semnuclmed.2024.05.012
[42]
Kim, Y.J., Ha, S. and Kim, Y. (2020) Cardiac Amyloidosis Imaging with Amyloid Positron Emission Tomography: A Systematic Review and Meta-Analysis. Journal of Nuclear Cardiology, 27, 123-132. https://doi.org/10.1007/s12350-018-1365-x
[43]
Bozkurt, B., Colvin, M., Cook, J., Cooper, L.T., Deswal, A., Fonarow, G.C., et al. (2016) Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement from the American Heart Association. Circulation, 134, e579-e646. https://doi.org/10.1161/cir.0000000000000455
[44]
Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R.H., Ferrari, V.A., et al. (2021) ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2—Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 14, e000029. https://doi.org/10.1161/hci.0000000000000029
[45]
De Carli, G., Mandoli, G.E., Salvatici, C., Biagioni, G., Marallo, C., Turchini, F., et al. (2023) Speckle Tracking Echocardiography in Plasma Cell Disorders: The Role of Advanced Imaging in the Early Diagnosis of AL Systemic Cardiac Amyloidosis. International Journal of Cardiology, 389, Article 131599. https://doi.org/10.1016/j.ijcard.2023.131599
[46]
del Carmen Mallón Araujo, M., Casas, E.A.J., Casas, C.A.J., Monzonis, M.A.M., Morell, Á.R. and Núñez, V.P. (2024) Cardiac Scintigraphy and Echocardiography Assessment in the Diagnosis of Transthyretin Cardiac Amyloidosis. The International Journal of Cardiovascular Imaging, 40, 415-424. https://doi.org/10.1007/s10554-023-02987-8
